Karen A.  Dawes net worth and biography

Karen Dawes Biography and Net Worth

Director of Repligen
Karen A. Dawes, Chairperson of the Board, has served as a director of Repligen since September 2005. She is currently President of Knowledgeable Decisions, LLC, a management consulting firm. Ms. Dawes served from 1999 to 2003 as Senior Vice President and U.S. Business Group Head for Bayer Corporation’s U.S. Pharmaceuticals Group. Prior to joining Bayer, she was Senior Vice President, Global Strategic Marketing, at Wyeth LLC (“Wyeth”), a pharmaceutical company (formerly known as American Home Products), where she held responsibility for worldwide strategic marketing. Ms. Dawes also served as Vice President, Commercial Operations for Genetics Institute, Inc., which was acquired by Wyeth in January 1997, designing and implementing that company’s initial commercialization strategy to launch BeneFIX® and Neumega®. Ms. Dawes began her pharmaceuticals industry career at Pfizer, Inc. where, from 1984 to 1994, she held a number of marketing positions, serving most recently as Vice President, Marketing of the Pratt Division. At Pfizer, she directed launches of Glucotrol®/Glucotrol XL®, Zoloft®, and Cardura®. Ms. Dawes also serves on the board of directors of two publicly traded companies: PaxMedica Therapeutics and Medicenna Therapeutics Corp, one private company, Vaccitech Limited, and on one not-for-profit company, Medicines 360. Ms. Dawes received a B.A. and M.A. in English from Simmons College and an M.B.A. from Harvard University Graduate School of Business. Ms. Dawes’ qualifications to sit on the Company’s Board include her extensive strategic experience in both a managerial and consulting capacity with pharmaceutical companies as well as her considerable commercial background.

What is Karen A. Dawes' net worth?

The estimated net worth of Karen A. Dawes is at least $10.75 million as of February 27th, 2024. Ms. Dawes owns 87,367 shares of Repligen stock worth more than $10,746,141 as of June 19th. This net worth estimate does not reflect any other investments that Ms. Dawes may own. Learn More about Karen A. Dawes' net worth.

How do I contact Karen A. Dawes?

The corporate mailing address for Ms. Dawes and other Repligen executives is 41 SEYON STREET BUILDING 1 SUITE 100, WALTHAM MA, 02453. Repligen can also be reached via phone at (781) 250-0111 and via email at [email protected]. Learn More on Karen A. Dawes' contact information.

Has Karen A. Dawes been buying or selling shares of Repligen?

Karen A. Dawes has not been actively trading shares of Repligen during the last ninety days. Most recently, Karen A. Dawes sold 1,000 shares of the business's stock in a transaction on Tuesday, February 27th. The shares were sold at an average price of $193.35, for a transaction totalling $193,350.00. Following the completion of the sale, the director now directly owns 87,367 shares of the company's stock, valued at $16,892,409.45. Learn More on Karen A. Dawes' trading history.

Who are Repligen's active insiders?

Repligen's insider roster includes Nicolas Barthelemy (Director), James Bylund (SVP), Karen Dawes (Director), Carrie Eglinton Manner (Director), Christine Gebski (Insider), Anthony Hunt (CEO), Ralf Kuriyel (VP), Martin Madaus (Director), Thomas Ryan, Jr. (Director), and Jon Snodgres (CFO). Learn More on Repligen's active insiders.

Are insiders buying or selling shares of Repligen?

In the last year, Repligen insiders bought shares 2 times. They purchased a total of 3,615 shares worth more than $449,938.10. In the last year, insiders at the biotechnology company sold shares 7 times. They sold a total of 50,307 shares worth more than $9,119,848.49. The most recent insider tranaction occured on June, 14th when Director Martin D Madaus bought 1,615 shares worth more than $201,778.10. Insiders at Repligen own 1.2% of the company. Learn More about insider trades at Repligen.

Information on this page was last updated on 6/14/2024.

Karen A. Dawes Insider Trading History at Repligen

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/27/2024Sell1,000$193.35$193,350.0087,367View SEC Filing Icon  
8/29/2023Sell850$171.38$145,673.0083,741View SEC Filing Icon  
9/9/2022Sell775$227.17$176,056.7576,401View SEC Filing Icon  
5/25/2022Sell14,715$150.51$2,214,754.6576,532View SEC Filing Icon  
11/2/2021Sell2,400$303.94$729,456.00View SEC Filing Icon  
9/14/2021Sell274$294.26$80,627.2493,908View SEC Filing Icon  
8/17/2021Sell17,514$253.77$4,444,527.78111,953View SEC Filing Icon  
7/20/2021Sell4,585$202.09$926,582.65View SEC Filing Icon  
5/11/2021Sell285$176.85$50,402.25115,734View SEC Filing Icon  
6/18/2020Sell18,705$115.20$2,154,816.00116,762View SEC Filing Icon  
5/20/2020Sell517$139.44$72,090.48119,946View SEC Filing Icon  
5/18/2020Sell1,600$137.78$220,448.00121,556View SEC Filing Icon  
4/20/2020Sell12,200$104.57$1,275,754.00121,234View SEC Filing Icon  
6/17/2019Sell1,295$77.35$100,168.25118,329View SEC Filing Icon  
5/11/2018Sell20,000$41.80$836,000.00114,957View SEC Filing Icon  
3/21/2017Sell2,521$34.12$86,016.5295,764View SEC Filing Icon  
6/21/2013Buy1,000$7.70$7,700.00View SEC Filing Icon  
See Full Table

Karen A. Dawes Buying and Selling Activity at Repligen

This chart shows Karen A Dawes's buying and selling at Repligen by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Repligen Company Overview

Repligen logo
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
Read More

Today's Range

Now: $123.00
Low: $121.16
High: $125.29

50 Day Range

MA: $158.40
Low: $123.00
High: $176.08

2 Week Range

Now: $123.00
Low: $110.45
High: $211.13

Volume

1,030,781 shs

Average Volume

685,086 shs

Market Capitalization

$6.87 billion

P/E Ratio

492.02

Dividend Yield

N/A

Beta

1.04